World's No 1 blood pressure med goes generic in US
This article was originally published in Scrip
The US patent on best-selling antihypertensive valsartan and the combination product valsartan plus the diuretic hydrochlorothiazide (Novartis's Diovan/Diovan HCT) expired on Friday, and Mylan has launched its generic version of Diovan HCT. At the same time, Novartis's generics division, Sandoz, has launched an authorised generic version of Diovan HCT. It would appear that no generic version of the monotherapy is yet available in the US, however.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.